Literature DB >> 2209763

Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro.

J Kurtzberg1, S G Carter.   

Abstract

We have studied the in vitro effects of carbovir as compared to 3'-azido-3'-deoxythymidine (AZT) on the growth of clonal bone marrow-derived hematopoietic progenitor cells. (-)Carbovir, the enantiomer with anti-human immunodeficiency virus (HIV) activity, exhibited significantly less toxicity to hematopoietic cells than AZT. These in vitro studies suggest that (-)carbovir will exhibit less hematologic toxicity in the therapy of patients infected with HIV either as a single agent or in combination with other agents that inhibit HIV proliferation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209763

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

1.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors:  S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  A cellular model for drug interactions on hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis.

Authors:  M C Léglise; P Darodes de Tailly; J L Vignot; M A Le Bot; A M Le Roux; C Riché
Journal:  Cell Biol Toxicol       Date:  1996-02       Impact factor: 6.691

3.  Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism.

Authors:  W B Parker; S C Shaddix; B J Bowdon; L M Rose; R Vince; W M Shannon; L L Bennett
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

4.  Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1.

Authors:  M S Smith; J A Kessler; C D Rankin; J S Pagano; J Kurtzberg; S G Carter
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

5.  Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats.

Authors:  Prashant Kumar; Yeruva Samrajya Lakshmi; Bhaskar C; Kishore Golla; Anand K Kondapi
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.